Tibulizumab
Based on 1 Customer Validation
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.86%
- CAS 番号: 1849636-24-3
- 分子量:201.43 kDa
-
保管条件:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Isotype
IgG4-kappa-[scFv-heavy-kappa]2
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
IL-17A 14 pM (Kd) |
BAFF 60 pM (Kd) |
体外実験
Tibulizumab (LY 3090106) binds to mouse BAFF with a KD of 340 nM and does not bind to mouse IL-17. Tibulizumab binds to cynomolgus BAFF and cynomolgus IL-17 with KD of 26.8 pM and 19 pM, respectively[1].
In HT-29 cells, Tibulizumab antagonizes the IL-17-induced secretion of CXCL1 in a concentration-dependent manner (IC50 of 2.00 nM). In T1165 cells, Tibulizumab blocks BAFF-induced proliferation in a concentration-dependent manner (IC50 of 0.064 nM). Tibulizumab simultaneously binds and blocks both BAFF and IL-17[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
In cynomolgus monkey, Tibulizumab (i.v, 0.3, 1, 5, or 20 mg/kg; or s.c, 5 mg/kg) suppresses B cell development and survival and remains functionally intact in circulation, with a prolonged half-life[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG4-kappa-[scFv-heavy-kappa]2
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized BAFF/TNFSF13B Protein, Human (CHO, HY-P7003) can bind Tibulizumab. The EC50 for this effect is 36.68 ng/mL. -
Immobilized IL-17A Protein, Human (HEK293, His, HY-P70527) can bind Tibulizumab. The EC50 for this effect is 19.5 ng/mL.
化学情報
-
CAS 番号 1849636-24-3
-
性状 Liquid
-
分子量 201.43 kDa
-
Color Colorless to light yellow
-
SMILES
[Tibulizumab]
-
別名
LY 3090106
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Tibulizumab 関連分類
HY-P99563 関連分類
Powered by Bioz